GlassScriptPhysician profile
Lisa M Keith
NPI 1194776013
$52,089.43
in general payments reported to CMS, 2019-2025
13 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $715 · 2022: $4,074 · 2023: $6,776 · 2024: $19K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $1,498 · Travel and Lodging: $685 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,985.31 |
| Food and Beverage | $1,497.98 |
| Travel and Lodging | $685.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $131.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $50,853.89 | 2021-2025 | Minimed 780g, Minimed 770g, Micra |
| Tandem Diabetes Care, INC. | $250.30 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $230.94 | 2021-2023 | Freestyle Libre |
| Dexcom, INC. | $219.05 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Insulet Corporation | $156.40 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $133.23 | 2021-2023 | |
| Sequel Med Tech, LLC | $84.16 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $66.19 | 2023-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $30.36 | 2023 | Mounjaro |
| Novo Nordisk INC | $18.39 | 2021 | |
| Beta Bionics, INC. | $18.17 | 2023 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $15.70 | 2021 | |
| Merck Sharp & Dohme LLC | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.